Novel nanobody-161 binds tumor necrosis factor receptor 2 (TNFR2) to exert an anti-tumor effect but does not block TNFα-binding
Nanobody-161 is a novel non-blocking TNFR2-antogonist that inhibits tumor growth without causing immunosuppression and is a promising candidate for safer and more effective therapy of solid tumors.
Authors
- Wenhai Zhang (ORCID: https://orcid.org/0000-0003-4974-656X)
- Junma Zhou
- Linlin Lu (ORCID: https://orcid.org/0000-0003-1647-1950)
- Xinglu Sun
- Hailiang Zheng
- Shanshan Dai (ORCID: https://orcid.org/0000-0001-5124-5882)
- Michael J. Zhang (ORCID: https://orcid.org/0000-0003-2537-2831)
- Shilong Fan (ORCID: https://orcid.org/0000-0001-9272-2438)
- Mei Ling Lim (ORCID: https://orcid.org/0000-0001-9898-5474)
- Xintian Yan
- Wanjing Wang (ORCID: https://orcid.org/0000-0003-0165-3161)
- Zhen Zhang (ORCID: https://orcid.org/0000-0003-4657-0589)
- Hui Guan (ORCID: https://orcid.org/0000-0001-8358-6526)
- Lei Pan (ORCID: https://orcid.org/0000-0003-3223-5034)
- Shuangqi Li (ORCID: https://orcid.org/0000-0002-1128-3865)
- Yuhao Hu (ORCID: https://orcid.org/0000-0003-1521-7838)
- Liang Huang (ORCID: https://orcid.org/0000-0002-2469-4313)
- Chao Kong (ORCID: https://orcid.org/0000-0003-2685-797X)
- Wenrong Wang
- Guojun Lang
Institutions
- Shanghai Jiao Tong University (CN)
- Sanyo (Japan) (JP)
- Beijing Institute of Water (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.3389/fimmu.2025.1694313
- Primary Topic
- Immune Response and Inflammation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Science and Technology Commission of Shanghai Municipality
- Science and Technology Innovation Plan Of Shanghai Science and Technology Commission